USP5 inhibition via bone marrow-targeted engineered exosomes for myeloproliferative neoplasms therapy
Abstract Myeloproliferative neoplasms (MPNs) are challenging to treat due to the complex bone marrow (BM) microenvironment and lack of curative therapies. Current treatments fail to eliminate malignant clones and face issues like drug resistance. This study addressed these challenges by identifying...
Saved in:
| Main Authors: | Wenjun Wang, Yufeng Jiang, Donglei Zhang, Xian Zhang, Qian Liang, Jun Shi, Yuan Zhou, Fuling Zhou |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | Journal of Nanobiotechnology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12951-025-03588-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinicopathological spectrum of BCR-ABL-Negative myeloproliferative neoplasms with correlation with janus-associated kinase 2 mutation
by: Roopa Dixith, et al.
Published: (2019-01-01) -
HMGB1 as a biomarker for myeloproliferative neoplasm complicated with atherosclerosis
by: Lunbi Wu, et al.
Published: (2025-05-01) -
Characteristics of regional epidemiological indicators of chronic myeloproliferative neoplasms
by: O. Yu. Vinogradova, et al.
Published: (2025-05-01) -
Case Report: Myelodysplastic/myeloproliferative neoplasm with concurrent SF3B1, ASXL1, JAK2 and CBL mutations and <15% bone marrow ringed sideroblasts
by: Yifan Wang, et al.
Published: (2025-07-01) -
Application of heteroduplex analysis for CALR mutation screening detection in patients with Ph-myeloproliferative neoplasms
by: T. N. Subbotina, et al.
Published: (2021-06-01)